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Cystic fibrosis (CF) is a monogenic inherited disease
characterized by irreversible chronic lung obstruction,
pancreatic involvement and altered sweat electrolyte
level.1 In the last 10 years more than 1300 different
mutations of cystic fibrosis transmembrane receptor (CFTR)
have been reported, each associated with a characteristic
phenotype.2–4
Here we describe the peculiar phenotype of a cystic
fibrosis patient with a rare ‘‘mild’’ CFTR mutation, known as
2789+5G-A, and 2789+5G-A/DF508 genotype. Clinical
history is reported in detail and compared with phenotypesElsevier Ltd. All rights reserved.
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receptor; CAVD, congenital
586710; fax: +39 577 280744.of patients compound-heterozygous for the same mutations
(2789+5G-A/DF508).
Case report
A 39-year-old male, in good clinical condition, was referred
to us with obstructive azoospermic sterility. Imaging revealed
bilateral absence of the vas deferens. Genetic molecular
analysis for common CFTR gene mutations in DNA of
peripheral leucocytes showed a rare genotype, 2789+5G-
A/DF508, suggesting cystic fibrosis. Medical history revealed
hospitalization for acute episodes of severe weakness,
profuse sweating, vomiting, myalgia and polyuria at 18 and
20 years of age. Hypokalemia, metabolic alkalosis and mild
hyperglycaemia were found. The patient was discharged with
a suggested diagnosis of periodic hypokalemic paralysis.
Hiatal hernia and gastroesophageal reflux were also de-
tected. Hydration and potassium supplementation in summer
prevented further episodes. At 30 years of age, the patient
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treated with oral therapy. On referral, the patient com-
plained of gastroesophageal reflux; he had no respiratory
symptoms, recurrent respiratory infections or nasal polyps.
Physical examination was normal; nutritional status and
respiratory and abdominal examinations were within normal
limits. Routine laboratory tests showed increased glycate
haemoglobin levels. The sweat chloride test showed very high
sweat chloride values (109.25meqL1). Lung function tests
showed absence of obstructive deficit (FEV1 107.9%; FVC
117.9%; TLCO 82.1%). The 6-min walking test on room air
excluded desaturation; Borg scale was zero before and after
the test. Blood gas analysis was normal with PaO2 of 98mmHg.
High resolution CT scan of the chest excluded lung involve-
ment; CT scan of the abdomen revealed reduced pancreatic
volume and many surface microcysts. Liver cirrhosis and
gastrointestinal obstructive syndrome were excluded.
The patient was counselled about his genetic disease and
advised to undergo complete regular follow-up in a centre
specialized in cystic fibrosis.
Discussion
This communication describes the phenotype of a CF patient
compound-heterozygous for 2789+5G-A/DF508 mutations.
The first report of splice site mutation 2789+5G-A (a G–A
substitution at nucleotide 2789 in intron 14b) associated
with mild cystic fibrosis, concerned a group of related
subjects.5 It was recently estimated that this mutation
accounts for 0.1% of CF chromosomes in the world6 and has
different frequencies in different geographic areas.7,8
Mutation 2789+5G-A was subsequently reported in homo-
zygotes and compound-heterozygotes with CFTR ‘‘mild’’
mutations and congenital absence of vas deferens (CAVD).9
A feature of our case was unusual presentation of the
disease. In most CF patients, onset is associated with
respiratory or gastrointestinal symptoms. In our patient
the first signs were hypokalemia and electrolyte abnormal-
ities, which were not recognized by the doctors. Dave et al.
and Bates et al. reported two cases of CF in which diagnosis
was based on severe hypokalemia, metabolic alkalosis, high
chloride levels in sweat and sodium loss as presenting
symptoms; they concluded that it was advisable to consider
CF, especially in young subjects with hypokalemia and
alkalosis and no history of renal or gastrointestinal diseases.
In 2005, Dugueperoux et al. studied the French CF
Registry and matched the phenotype of a group of CF
patients, compound-heterozygous for 2789+5G-A/DF508
mutations, with the clinical features of DF508 homozygotes.
They concluded that CF heterozygotes had a milder
phenotype than homozygous patients, as well as higher
age at diagnosis, lower frequency of pancreatic insuffi-
ciency, better anthropometric measures and no meconium
ileus because the splice site 2789+5G-A mutation is
associated with partially defective receptor production
and small amounts of normal CFTR. Increased sweat chloride
values and respiratory involvement were common features
of both groups of CF patients. When we compared the
clinical findings of our patient with those of heterozygous CF
patients reported by Dugueperoux et al., some differences
emerged: age at diagnosis (our patient was much older: 39versus 16.6712.7 years), absence of respiratory involve-
ment and presence of diabetes mellitus (never reported in
heterozygous CF patients and very frequent in homozygotes
for the DF508 mutation). Moreover, our patient had CAVD
which was why molecular analysis of the CFTR gene was
done. This anomaly was not found in Dugueperoux’s
population of heterozygotes. The main similarities between
the phenotype of our patient and those already reported by
Dugueperoux included high sweat concentrations of chlor-
ide, gastroesophageal reflux, normal body mass index.
In conclusion, although the phenotype of our CF patient,
compound-heterozygous for 2789+5G-A/DF508 mutations,
may be associated with a milder course of the disease, it has
the unusual features of CAVD, pancreatic involvement and
diabetes mellitus, rather than respiratory involvement. The
clinical presentation of our case was also unusual, under-
lining the importance of considering the possibility of CF in
apparently healthy persons with episodes of severe hypoka-
lemia and metabolic alkalosis. The expression of clinical
phenotype in our patient may be the result of different
penetrance of the two mutations and/or the effect of
modifying genes.
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